579 results on '"A. Haverich"'
Search Results
2. (1264) Recipients of Extended Criteria Ex Situ Preserved Lungs Display Higher Plasma Levels of Cytokines and Endothelial Markers after Lung Transplantation Without Higher PGD Scores
3. (410) Perioperative Desensitization Changes the Plasma Cytokine Milieu in Lung Transplant Patients with Preformed Donor Specific Antibodies
4. 12-Year Experience with Postoperatively Extended Intraoperative Extracorporeal Membrane Oxygenation in Lung Transplantation for Patients with Severe Pulmonary Arterial Hypertension
5. (101) Nine-Year Experience with Treatment of Early Detectable Donor Specific Anti-HLA Antibodies in Pediatric Lung Transplant Recipients
6. (120) Heart Preservation with the Organ Care System in Extended Criteria Donor Hearts: A Single Center Experience
7. (348) Longitudinal Dynamics of SARS-CoV-2 Spike-Specific Antibody Responses in Patients on Waiting List and after Lung Transplantation
8. Outcomes in patients with cardiac amyloidosis undergoing heart transplantation: the eurotransplant experience
9. Indications and outcome after lung transplantation in children under 12 years of age: A 16-year single center experience
10. (906) Impact of Donor Quality on Recipient Outcomes in Lung Transplantation: 12-Year Single-Center Experience Using the Eurotransplant Lung Donor Score
11. (1264) Recipients of Extended Criteria Ex Situ Preserved Lungs Display Higher Plasma Levels of Cytokines and Endothelial Markers after Lung Transplantation Without Higher PGD Scores
12. (908) Does Donor-Recipient Sex Mismatch Have an Influence on Long Term Outcomes after Lung Transplantation? An Experience of a High Volume Center
13. (882) Nine-Year Results of an IgA-And IgM-Enriched Human Immunoglobulin-Based Therapy for Early Detectable Anti-HLA Donor Specific Antibodies after Lung Transplantation
14. (101) Nine-Year Experience with Treatment of Early Detectable Donor Specific Anti-HLA Antibodies in Pediatric Lung Transplant Recipients
15. (348) Longitudinal Dynamics of SARS-CoV-2 Spike-Specific Antibody Responses in Patients on Waiting List and after Lung Transplantation
16. (402) 12-Year Experience with Postoperatively Extended Intraoperative Extracorporeal Membrane Oxygenation in Lung Transplantation for Patients with Severe Pulmonary Arterial Hypertension
17. (120) Heart Preservation with the Organ Care System in Extended Criteria Donor Hearts: A Single Center Experience
18. (410) Perioperative Desensitization Changes the Plasma Cytokine Milieu in Lung Transplant Patients with Preformed Donor Specific Antibodies
19. Eight-Year Results of an IgA- and IgM-Enriched Human Immunoglobulin-Based Therapy for Early Detectable Anti-HLA Donor Specific Antibodies After Lung Transplantation
20. Long-Term Results of the OCS Lung Expand International Trial Using Organ Care System Lung Perfusion System (OCS) in Extended-Criteria Donor (ECD) and Donation After Circulatory Death (DCD) Donor Lungs
21. Risk Factors for the Development of Early Anti-HLA Donor Specific Antibodies After Lung Transplantation: The Role of Primary Graft Dysfunction
22. Lung Transplant Recipients Developing Early DSAs within the First Month Are Characterized by a Higher Frequency of Naïve and a Lower Frequency of Memory B Cells
23. Primary Graft Dysfunction Following Lung Transplantation is Associated with Increased In Vivo T Cell Alloreactivity: Evidence from a Humanized Mouse Model
24. Using Donor Lungs ≥70 Years of Age for Transplantation - Do Long-Term Outcomes Justify the Use?
25. Perioperative Desensitization with IgA- and IgM-Enriched Human Immunoglobulins Allows Safe Lung Transplantation in Patients with Preformed Donor Specific Antibodies
26. Liver-First Strategy for Combined Lung and Liver Transplantation: 15-Year Single-Center Experience
27. Donor T and NK Cells with a Special Tissue-Resident Memory Phenotype Migrate into the Periphery of Lung Transplant Recipients - A Potential Feature for Tolerance Development
28. Out of the Frying-Pan and into the Fire: Transplant Candidate Selection in Acute Lung Failure Due to SARS-CoV-2 Infection
29. Lung Transplantation and Concomitant Coronary Artery Bypass Grafting Does Not Impair Patient Outcomes: Insights from a Single-Center Experience
30. Variances in Humoral Responses to Different Spike Protein Domains After SARS-CoV-2 Vaccination in Lung and Heart Transplant Recipients
31. Indications and outcome after lung transplantation in children under 12 years of age: A 16-year single center experience
32. Long-term outcomes after intraoperative extracorporeal membrane oxygenation during lung transplantation
33. Out of the Frying-Pan and into the Fire: Transplant Candidate Selection in Acute Lung Failure Due to SARS-CoV-2 Infection
34. Liver-First Strategy for Combined Lung and Liver Transplantation: 15-Year Single-Center Experience
35. Lung Transplant Recipients Developing Early DSAs within the First Month Are Characterized by a Higher Frequency of Naïve and a Lower Frequency of Memory B Cells
36. Risk Factors for the Development of Early Anti-HLA Donor Specific Antibodies After Lung Transplantation: The Role of Primary Graft Dysfunction
37. Donor T and NK Cells with a Special Tissue-Resident Memory Phenotype Migrate into the Periphery of Lung Transplant Recipients - A Potential Feature for Tolerance Development
38. Primary Graft Dysfunction Following Lung Transplantation is Associated with Increased In Vivo T Cell Alloreactivity: Evidence from a Humanized Mouse Model
39. Perioperative Desensitization with IgA- and IgM-Enriched Human Immunoglobulins Allows Safe Lung Transplantation in Patients with Preformed Donor Specific Antibodies
40. Long-Term Results of the OCS Lung Expand International Trial Using Organ Care System Lung Perfusion System (OCS) in Extended-Criteria Donor (ECD) and Donation After Circulatory Death (DCD) Donor Lungs
41. Lung Transplantation and Concomitant Coronary Artery Bypass Grafting Does Not Impair Patient Outcomes: Insights from a Single-Center Experience
42. Eight-Year Results of an IgA- and IgM-Enriched Human Immunoglobulin-Based Therapy for Early Detectable Anti-HLA Donor Specific Antibodies After Lung Transplantation
43. Using Donor Lungs ≥70 Years of Age for Transplantation - Do Long-Term Outcomes Justify the Use?
44. Seven-Year Clinical Results of an IgA-and IgM-Enriched Human Immunoglobulin-Based Therapy for Antibody-Mediated Rejection after Lung Transplantation
45. Heart-Associated Cytokine and Endothelial Patterns Dominate the Ischemia/Reperfusion Response in Recipients of Combined Heart/Lung Transplantation in Comparison to Lung Transplantation
46. Biologisation of the Left Ventricular Assist Device
47. Treatment of Anti-HLA Donor-Specific Antibodies in Heart Transplantation: A Single-Center Experience
48. Ex Situ Heart Perfusion and Standard of Care Cold Storage Differentially Affect the Ischemic Secretome of Donor Hearts in Perfusates but Not the Reperfusion Response in Recipient Plasma
49. Fifteen-Year Single Center Experience with Lung Transplantation in Pediatric Patients Younger Than 12 Years Old
50. Towards Biohybrid Lung Development - Extracellular Matrix Synthesis Increases Flow-Resilience of Endothelialized Hollow Fibre Membranes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.